DEVELOPMENT OF A CHLAMYDIAL VACCINE FOR KOALAS. Peter Timms et al.
|
|
|
- Erick Wheeler
- 6 years ago
- Views:
Transcription
1 DEVELOPMENT OF A CHLAMYDIAL VACCINE FOR KOALAS Peter Timms et al.
2
3
4
5 Keratoconjunctivitis
6 Reproductive tract disease
7 Current taxonomy for Chlamydiae C. ibidis C. muridarum C. gallinacea C. felis C. avium C. caviae C. psittaci C. abortus C. trachomatis C. pneumoniae C. suis C. pecorum
8 Goal : To develop a vaccine to protect koalas against C.pecorum infection and disease Vaccine should result in; Antibodies Specific & high titres Neutralising Present at mucosal sites T cell response Lymphocyte proliferation Cytokines (interferon-gamma) Two types of vaccine Prophalytic Therapeutic
9 Basic vaccine formulation 1. Chlamydial antigen 1. Recombinant MOMP proteins 2. Koala C.pecorum 3 genotypes 2. Adjuvant 1. Iscomatrix; Tri-adjuvant (VIDO) 3. Delivery : subcutaneous 4. Assessment 1. Swab eyes and UGT and measure infection (qpcr) load 2. Clinical disease
10 The 10-year project 1. Can koalas produce an immune response to chlamydial antigens 2. Is the vaccine safe to give to animals with current infection / disease 3. Can a vaccine do something that natural infection is currently not doing 4. Is there cross-strain immune recognition 5. Vaccination of male as well as female koalas 6. Move from a multi-dose to a single dose vaccine 7. Develop new koala immunological reagents 8. Evaluate the vaccine under field conditions 9. What is the basis of protection 10. Can you vaccinate against disease
11 Production of in vitro neutralising antibodies following vaccination Healthy vaccine Healthy placebo Diseased vaccine Diseased placebo
12 Production of a T cell response Healthy vaccine Healthy placebo Diseased vaccine Diseased placebo
13 The 10-year project 1. Can koalas produce an immune response to chlamydial antigens 2. Is the vaccine safe to give to animals with current infection / disease 3. Can a vaccine do something that natural infection is currently not doing 4. Is there cross-strain immune recognition 5. Vaccination of male as well as female koalas 6. Move from a multi-dose to a single dose vaccine 7. Develop new koala immunological reagents 8. Evaluate the vaccine under field conditions 9. What is the basis of protection 10. Can you vaccinate against disease
14
15 First major field trial 60 free-ranging koalas; 30 Vaccine & 30 Control Vaccine Antigen: Major Outer Membrane Protein (MOMP) Adjuvant: Immune Stimulating Complex (ISC) Immunisation Schedule : Days 0, 30 and 60 Analysis IgG antibody production; Cytokine production Chlamydia infection load as determined by qpcr Incidence of new disease
16 Chlamydiaload decreases in vaccinated animals(ocular) Unvaccinated S1 Mdnof 39 [IQR = ] S2 Mdn119.6 [IQR = ] Wilcoxin signed rank test z= , p = 0.116, r= 0.45
![Chlamydiaload decreases in vaccinated animals(ocular) Vaccinated Unvaccinated S1 Mdn= 13.9 [IQR = 10.7-48.2] S2 Mdn= 0 [IQR = 0-21.](/docs-images/77/75322868/images/17-1.jpg "8] Wilcoxin signed rank test z= -2.310, p = 0.021, r= 0.54 S1 Mdnof 39 [IQR = 20.3 76.4] S2 Mdn119.6 [IQR = 10.6 204.1] Wilcoxin signed rank test z= -1.")
17 Chlamydiaload decreases in vaccinated animals(ocular) Vaccinated Unvaccinated S1 Mdn= 13.9 [IQR = ] S2 Mdn= 0 [IQR = ] Wilcoxin signed rank test z= , p = 0.021, r= 0.54 S1 Mdnof 39 [IQR = ] S2 Mdn119.6 [IQR = ] Wilcoxin signed rank test z= , p = 0.116, r= 0.45
![53] Wilcoxin signed rank test z = -2.366, p= 0.018, r= -0.89 S1, Mdn= 57.](/docs-images/77/75322868/images/18-1.jpg "9 [IQR = 41.6-131.2] S2, Mdn= 12.7 [IQR = 0 143.")
18 Chlamydiaload decreases in vaccinated animals(ugt) Vaccinated Unvaccinated S1 Mdn= 31.4 [IQR = ] S2 Mdn= 0, [IQR = ] Wilcoxin signed rank test z = , p= 0.018, r= S1, Mdn= 57.9 [IQR = ] S2, Mdn= 12.7 [IQR = ] Wilcoxin signed rank test z= , p = 0.422, r= -0.22
19 Vaccinated animals do not progress to a diseased state 0% 11.5%
20 The 10-year project 1. Can koalas produce an immune response to chlamydial antigens 2. Is the vaccine safe to give to animals with current infection / disease 3. Can a vaccine do something that natural infection is currently not doing 4. Is there cross-strain immune recognition 5. Vaccination of male as well as female koalas 6. Move from a multi-dose to a single dose vaccine 7. Develop new koala immunological reagents 8. Evaluate the vaccine under field conditions 9. What is the basis of protection 10. Can you vaccinate against disease
21 In vitro neutralisation antibody levels
22 Mapping of the MOMP epitopes : PepScan technology
23 Absorption of sera against peptides and evaluation of remaining in vitro neutralisation ability
24
25 Acknowledgements Partners University of Sunshine Coast Queensland Univ Technology Gold Coast City Council Moreton Bay Regional Council DEHP DTMR; MBRL team Lone Pine Koala Sanctuary Friends of the Koala VIDO, Canada Endeavour Veterinary Ecology Australia Zoo Wildlife Hospital Koala Action Inc. Redland City Council Key people P Timms K Beagley A Polkinghorne C Waugh M Mathew S A Khan P Kanyoka A Kollipara S Nyari M Descoleux C Mangar
Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.
Title Studies of SARS virus vaccines Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 Issued
Dr Olga Pleguezuelos CSO and Project Manager at SEEK
Dr Olga Pleguezuelos CSO and Project Manager at SEEK Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hvivo to accelerate the development of a Mosquito Vaccine (AGS-v) and Broad-
Australian Chlamydia Conference November, 2017
Australian Chlamydia Conference 21-22 November, 2017 Aerial conference centre, Building 10 University of Technology Sydney Conference Chair: Dr Willa Huston Wilhelmina.Huston@uts.edu.au @willaonthego Conference
Longevity of protection in cattle following vaccination with emergency FMD vaccines from the UK strategic reserve
Longevity of protection in cattle following vaccination with emergency FMD vaccines from the UK strategic reserve Sarah Cox, Satya Parida, Pip Hamblin, Bartek Bankowski Veronica Carr, David Paton and Paul
Cover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
The immune response against Chlamydia suis genital tract infection partially protects against re-infection
UGhent Center for Strategic Prophylaxis and Vaccine Development The immune response against Chlamydia suis genital tract infection partially protects against re-infection E. De Clercq 1, B. Devriendt 2,
Updated: 26 August 2010
Australian Technical Advisory Group on Immunisation (ATAGI) Updated advice on the use of pandemic and seasonal influenza vaccines in children
Molecular dynamics and mode of transmission of Koala Retrovirus (KoRV) as it invades and. Sippy Downs Drive, Sippy Downs, Queensland, 4556, Australia
JVI Accepted Manuscript Posted Online 13 December 2017 J. Virol. doi:10.1128/jvi.01871-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 Molecular dynamics and mode of transmission
Understanding basic immunology. Dr Mary Nowlan
Understanding basic immunology Dr Mary Nowlan 1 Immunology Immunology the study of how the body fights disease and infection Immunity State of being able to resist a particular infection or toxin 2 Overview
Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
Identification of unusual Chlamydia pecorum genotypes in Victorian koalas (Phascolarctos cinereus) and clinical variables associated with infection
Journal of Medical Microbiology (2016), 65, 420 428 DOI 10.1099/jmm.0.000241 Identification of unusual Chlamydia pecorum genotypes in Victorian koalas (Phascolarctos cinereus) and clinical variables associated
100 years of Influenza Pandemic and the prospects for new influenza vaccines
100 years of Influenza Pandemic and the prospects for new influenza vaccines Dr John McCauley Director, WHO Collaborating Centre for Reference and Research on influenza The Francis Crick Institute London
ENZYME IMMUNOASSAYS FOR THE DIAGNOSIS OF CHLAMYDIA INFECTIONS. Chlamydia sp. Chlamydia pneumoniae Chlamydia trachomatis INFECTIOUS SEROLOGY
INFECTIOUS SEROLOGY Bacteriology ENZYME IMMUNOASSAYS FOR THE DIAGNOSIS OF CHLAMYDIA INFECTIONS Chlamydia sp. Chlamydia pneumoniae Chlamydia trachomatis ELISA and IMMUNOBLOT kits are optimized and validated
They determine if there will be an immune response. Determine functions associated with immune response, but not specific to Ag.
Appendices A They determine if there will be an immune response. Antigen receptor genes in T cells (TCR) and B cell (Ig) Determine functions associated with immune response, but not specific to Ag. MHC
Inflammasome activation in ruminant cells infected with Chlamydia abortus
This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions
INTERFERON GAMMA AND PENICILLIN TREATMENT ANU CHACKO. Masters of Advanced Biotechnology, (2009) The University of Queensland, Australia
COMPARISON OF HUMAN AND ANIMAL CHLAMYDIA PNEUMONIAE RESPONSES TO INTERFERON GAMMA AND PENICILLIN TREATMENT ANU CHACKO Masters of Advanced Biotechnology, (2009) The University of Queensland, Australia A
Update on influenza monitoring and vaccine development
Update on influenza monitoring and vaccine development Annette Fox WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity 1 Outline Why
Immunity & Vaccination John Helps BVetMed CertSAM MRCVS Senior Technical Manager- CABU
Immunity & Vaccination John Helps BVetMed CertSAM MRCVS Senior Technical Manager- CABU Overview Immune system Vaccines and vaccination Nobivac Vaccine range The Immune System Innate Immunity Acquired Immunity
Novel Vaccine Delivery Technology
Novel Vaccine Delivery Technology Philip Willson Vaccine & Infectious Disease Organization, 120 Veterinary Road, Saskatoon, SK S7N 5E3. Email: philip.willson@usask.ca Introduction Infections of the respiratory
Jyotika Sharma, Feng Dong, Mustak Pirbhai, and Guangming Zhong*
INFECTION AND IMMUNITY, July 2005, p. 4414 4419 Vol. 73, No. 7 0019-9567/05/$08.00 0 doi:10.1128/iai.73.7.4414 4419.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Inhibition
Update of Childhood Vaccination on the Gold Coast
Update of Childhood Vaccination on the Gold Coast 1 Percentage IMMUNISATION GPII Division % Coverage Rates 88.5 88 87.5 87 Preliminary Recalc 86.5 86 Feb-09 May-09 Aug-09 Nov-09 Quarter Percentage IMMUNISATION
Fact sheet. Introductory statement. Aetiology
Koala retrovirus (KoRV) Fact sheet Introductory statement The term koala retrovirus (KoRV) refers to a group of viruses specific to koalas. The viruses display a range of transmission behaviours (inherited
New Technology in Vaccine Engineering
Viruses in May Katoomba, August, 2012 New Technology in Vaccine Engineering Anton Middelberg Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia Introduction
Chlamydia sp. Chlamydia pneumoniae Chlamydia trachomatis
Chlamydia sp. Chlamydia pneumoniae Chlamydia trachomatis Enzyme immunoassays for the diagnosis of Chlamydia infection ELISA, IMMUNOBLOT and MICROBLOT-ARRAY kits are optimized and validated for detection
CEVAC CEVAC BROILER ND K / 5000 doses
CEVAC BROILER ND K / 5 doses CEVAC BROILER ND K Newcastle disease a permanent threat Newcastle Disease is highly contagious and exists in a wide range of forms. It is one of the four major poultry diseases
Immunology and the middle ear Andrew Riordan
Immunology and the middle ear Andrew Riordan The Immune system is NOT there; To baffle medical students To keep Immunologists in a job To encourage experiments on mice The Immune system IS there as a defence
Chlamydia trachomatis Vaccine Research through the Years
Hindawi Publishing Corporation Infectious Diseases in Obstetrics and Gynecology Volume 2011, Article ID 963513, 9 pages doi:10.1155/2011/963513 Review Article Chlamydia trachomatis Vaccine Research through
Immunoprotective effect of plasmid-less Chlamydia strain
Immunoprotective effect of plasmid-less Chlamydia strain A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates by Laszlo Kari, William M. Whitmire, Norma Olivares-Zavaleta,
Systematic Review of Non-Specific Immunological Effects of Vaccination
Systematic Review of Non-Specific Immunological Effects of Vaccination Professor Andrew J Pollard Dr Rama Kandasamy Merryn Voysey University of Oxford Immunology Non-specific effects of the immune system
Chlamydia pneumoniae PCR reagents Detection with real time PCR reagents
Chlamydia pneumoniae PCR reagents Detection with real time PCR reagents Overview:... 1 Products... 2 C. pneumoniae FAM-BHQ1 Primer-probe PP3400 0.055ml... 2 AttoMaster 2X Mix for qpcr AM10 1.25 ml... 2
Mechanismof interferon- -mediated anti-chlamydia infection
2009 6 4 2 Journal of Microbes and Infection, June 2009, Vol. 4, No. 2 103,,, 421001 :,,, ; : ; ; ; Mechanismof interferon- -mediated anti-chlamydia infection TANG Guo-Fang, LI Zhong-Yu, WU Yi-Mou Institute
Incorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
Regulation of FMD vaccines within the European Union
Introduction Regulation of FMD vaccines within the European Union K De Clercq 1 and D K J Mackay 2 Appendix 36 The EUFMD European Pharmacopoeia Working Group made a proposal for revision of the FMD vaccine
Antigens and Immunogens
Background 1. Medical Importance of Immune System (vaccines, immunodeficiency diseases, hypersensitivity) 2. How the Immune System Works (innate & adaptive immune mech., B/T cells, Abs, Cytokines) 2. Cells
Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines
247 Appendix 31 Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines S. J Cox and P. V. Barnett Institute for Animal Health, Pirbright
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
The University of Sydney Page 1 ONE HEALTH TEAM. Australian Rickettsial Reference Laboratory
Longevity of immunity following Q fever vaccination A Multidisciplinary One Health Team Presented by Associate Professor Nicholas Wood On behalf of NHMRC Q fever grant APP1049557 The University of Sydney
Update on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009
Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine
C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.
Immunology - Problem Drill 13: T- Cell Mediated Immunity Question No. 1 of 10 1. During Antibody-dependent cell mediated cytotoxicity (ADCC), the antibody acts like a bridge between the specific antigen
The Challenge and Approach of Developing a Novel Anti-Nicotine Vaccine. Heather L. Davis, PhD Pfizer Vaccine Immunotherapeutics Ottawa, Canada
The Challenge and Approach of Developing a Novel Anti-Nicotine Vaccine Heather L. Davis, PhD Pfizer Vaccine Immunotherapeutics Ottawa, Canada Disclaimer This work was funded by Pfizer and was conducted
The World Health Organization (WHO) estimate that vaccination averts 2-3 million deaths per year (in all age groups), and up to 1.
Vaccination The World Health Organization (WHO) estimate that vaccination averts 2-3 million deaths per year (in all age groups), and up to 1.5 million children die each year due to diseases which could
Chapter 22: The Lymphatic System and Immunity
Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease Jeffrey J. Stoddard, MD, FAAP Head, Global Medical Affairs Novartis Vaccines and Diagnostics
VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON
VIRUSES Biology Applications Control David R. Harper GS Garland Science Taylor & Francis Group NEW YORK AND LONDON vii Chapter 1 Virus Structure and 2.2 VIRUS MORPHOLOGY 26 Infection 1 2.3 VIRAL CLASSIFICATION
This is the author s version of a work that was submitted/accepted for publication in the following source:
This is the author s version of a work that was submitted/accepted for publication in the following source: Hafner, Louise M., Cunningham, Kelly, & Beagley, Kenneth W. (2013) Ovarian steroid hormones:
Foot and Mouth Disease Vaccine Research and Development in India
Foot and Mouth Disease Vaccine Research and Development in India R.Venkataramanan Indian Veterinary Research Institute, Hebbal, Bangalore 560 024 Foot and Mouth Disease in India Present Status Large Susceptible
Chapter 35 Active Reading Guide The Immune System
Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process
ELISA test to detect Chlamydophila pneumoniae IgG
J. Basic Microbiol. 42 (2002) 1, 13 18 (Departments of Microbiology and Surgery 1, University Hospital San Cecilio, University of Granada, School of Medicine, Granada, Spain) ELISA test to detect Chlamydophila
MORPHOLOGIC AND GENOMIC CHARACTERISATION OF THE KOALA CHLAMYDIA PNEUMONIAE STRAIN
MORPHOLOGIC AND GENOMIC CHARACTERISATION OF THE KOALA CHLAMYDIA PNEUMONIAE STRAIN Candice Melissa Mitchell Bachelor of Applied Science (Honours I), QUT 2006 Institute of Health and Biomedical Innovation
Adaptive Immunity: Specific Defenses of the Host
17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function
IOM Immunization Safety Review 11/12/2001. Immunological Competition and the Infant Immune Response to Vaccines
IOM Immunization Safety Review 11/12/2001 Immunological Competition and the Infant Immune Response to Vaccines Richard Insel University of Rochester Goals Neonatal and Infant Immune System Broad Effects
Feline infectious diseases: part one
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Feline infectious diseases: part one Author : Martin Atkinson Categories : Vets Date : June 1, 2009 Martin Atkinson debates
It s not just allo-antibodies that a red cell transfusion can stimulate
It s not just allo-antibodies that a red cell transfusion can stimulate Associate Professor Ralph Green Laboratory Medicine RMIT University Melbourne, Australia Transfusion practice Minimise risk of transmitting
EEHV Workshop Lauren L. Howard, DVM, Dipl. ACZM San Diego Zoo Safari Park
EEHV Workshop 2017 Lauren L. Howard, DVM, Dipl. ACZM San Diego Zoo Safari Park Workshop Attendees 78 Participants 9 Countries 21 talks 2 practicals Regional Summaries North America 35 cases in calves born
Prophylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge
Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype
11/25/2017. THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS BARRIER DEFENSES INNATE IMMUNITY OF VERTEBRATES
THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS Exoskeleton made of chitin forms the first barrier to pathogens Digestive system is protected by a chitin-based barrier and lysozyme,
Protocol Synopsis. Administrative information
Protocol Synopsis Item (SPIRIT item no.) Administrative information Title (1) Introduction Description of research question (6a) Description An optimal schedule for the post-polio eradication era: multicentre
Chlamydia sp. in free-ranging populations of hawks (Buteo sp.) in Northern California
Chlamydia sp. in free-ranging populations of hawks (Buteo sp.) in Northern California By CHARLENE MILAGROS LUJÁN VEGA B.M.V. (National San Marcos University) 2008 Med. Vet. (National San Marcos University)
Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
Chlamydia trachomatis IgG ELISA Kit
Chlamydia trachomatis IgG ELISA Kit Catalog Number KA2077 96 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
Serodiagnostics of paratuberculosis Kari R. Lybeck
Serodiagnostics of paratuberculosis Kari R. Lybeck Photo: Birte Graeber Paratuberculosis Paratuberculosis Mycobacterium avium subsp. paratuberculosis (MAP) Chronic, granulomatous enteritis and lymphadenitis
Vaccines of the future
Vaccines of the future Rino Rappuoli Conference on New Horizons for Vaccine Research and Innovation Session on Innovation on Vaccine Design Bruxelles, March 12 2014 Vaccination, the most effective medical
Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
EMA guidelines on influenza vaccines
EMA guidelines on influenza vaccines High level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination Presented by Manuela Mura on 30 April 2015 Scientific Officer
Development of a VP6 subunit rotavirus vaccine A dual role of VP6 as a vaccine antigen and an adjuvant
30 August 2018, Minsk 13TH INTERNATIONAL ROTAVIRUS SYMPOSIUM Development of a VP6 subunit rotavirus vaccine A dual role of VP6 as a vaccine antigen and an adjuvant Dr. Vesna Blazevic Head of Laboratory
Cancer Registry Report. Cancer Focus: Melanoma
Cancer Registry Report Cancer Focus: Melanoma In 2005, nearly 60,000 patients were diagnosed with melanoma, resulting in about 7800 deaths Fortunately, melanoma is often diagnosed in an early stage when
GSK s RSV vaccine product development overview
GSK s RSV vaccine product development overview Introduction GSK maternal and paediatricrsv programs are in early stage of development (Phase I/II) For both programs, GSK is targeting a global development
Chlamydiaceae Genomics Reveals Interspecies Admixture and the Recent Evolution of Chlamydia abortus Infecting Lower Mammalian Species and Humans
Chlamydiaceae Genomics Reveals Interspecies Admixture and the Recent Evolution of Chlamydia abortus Infecting Lower Mammalian Species and Humans Sandeep J. Joseph, Emory University Hanna Marti, Children
WHY IS THIS IMPORTANT?
CHAPTER 16 THE ADAPTIVE IMMUNE RESPONSE WHY IS THIS IMPORTANT? The adaptive immune system protects us from many infections The adaptive immune system has memory so we are not infected by the same pathogen
Nanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
Appendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Influenza Revised December 2014 Influenza 1.0 Provincial Reporting Confirmed cases of disease 2.0 Type
Phase of immune response
Antigen and antigen recognition by lymphocytes Antigen presentation to T lymphocytes Sanipa Suradhat Department of Veterinary Microbiology Faculty of Veterinary Science Phase of immune response 1 Phase
Immunity & How Vaccines Work
Immunity & How Vaccines Work Immunisation Study Day 30 th November 2016 Talk given today by Dr. Mary Fitzgerald Learning outcome To be able to describe in outline the immune system and how vaccines work
Proceedings of the Society for Theriogenology Annual Conference 2014
www.ivis.org Proceedings of the Society for Theriogenology Annual Conference 2014 Aug. 6-9, 2014 Portland, OR, USA Next SFT Meeting: Aug. 5-8, 2015 San Antonio, TX, USA Reprinted in the IVIS website with
Block 1. Immunology and Principles of Vaccination
The Institute for International Cooperation in Animal Biologics (IICAB) is offering a eleven-day Veterinary Biologics Training Program beginning May 9, 2007 in Ames, Iowa. The course is sponsored by the
Chapter 24 The Immune System
Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific
How does the body defend itself?
Prevention of Infection 2 Immunisation 3 rd BDS B. Martin Major World Causes Of Death COUNTRIES Developing Developed Total x10-6 Population 5400 (80%) 1200 (20%) 6600 CAUSE OF DEATH % % % Infectious diseases
WP6 (Lead Partner RUG) Clinical Trial Program
WP6 (Lead Partner RUG) Clinical Trial Program Eelko Hak, Work Package leader Groningen Research Institute of Pharmacy & Epidemiology, University of Groningen Double-Blind Randomized Controlled Phase IIb
ABSTRACT. The effect of Chlamydia on translocated Chlamydia-naïve koalas: a case study F. Santamaria A B and R. Schlagloth A. Australian.
The effect of Chlamydia on translocated Chlamydia-naïve koalas: a case study F. Santamaria A B and R. Schlagloth A A School of Medical and Applied Sciences Central Queensland University, Rockhampton, Australia
Immunology. Lecture ( 7 ) Dr, Baha,Hamdi,AL-Amedi Ph. D.Microbiology HOST DEFENSE
Immunology Lecture ( 7 ) Dr, Baha,Hamdi,AL-Amedi Ph. D.Microbiology HOST DEFENSE The Origin of Immune Concept-I The term Immunity-1 Latin word Immunitas :Protection from legal prosecution Biological definition:
Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis M Juliana McElrath, Stephen C De Rosa, Zoe Moodie, Sheri Dubey, Lisa Kierstead, Holly Janes, Olivier D Defawe, Donald
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
VACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
Therapeutic Cancer Vaccines
Therapeutic Cancer Vaccines Goal for all therapeutic cancer vaccines: To enhance the natural immune response so that it becomes an effective therapy Approaches being investigated in clinical studies: Whole
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
Richard Malik Centre for Veterinary Education The University of Sydney
Richard Malik Centre for Veterinary Education The University of Sydney 1 Pathology Update 3/8/2019 Pathology Update 3/8/2019 2 Pathology Update 3/8/2019 3 Pathology Update 3/8/2019 4 Pathology Update 3/8/2019
In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between
In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between the two, we also propose a classification system for
Report from the Pertussis Working Group
Report from the Pertussis Working Group Elizabeth Miller SAGE Member and Chair of the Pertussis Working Group 29 October 2009 Geneva Working Group Members Elizabeth Miller (chair), Health Protection Agency,
Lecture 9: T-cell Mediated Immunity
Lecture 9: T-cell Mediated Immunity Questions to Consider How do T cells know where to go? Questions to Consider How do T cells know where to go? How does antigen get targeted to a T cell expressing the
Intended Use. Introduction - 2 -
Intended Use The SeroCT - IgG kit is intended for the detection of IgG antibodies specific to C. trachomatis in human serum. The Savyon SeroCT - IgG kit is a new generation qualitative ELISA test which
The Adaptive Immune Response. B-cells
The Adaptive Immune Response B-cells The innate immune system provides immediate protection. The adaptive response takes time to develop and is antigen specific. Activation of B and T lymphocytes Naive
Trends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
Development and evaluation of a multi-antigen peptide ELISA for the diagnosis of Chlamydia trachomatis-related infertility in women
Journal of Medical Microbiology (2016), 65, 915 922 DOI 10.1099/jmm.0.000311 Development and evaluation of a multi-antigen peptide ELISA for the diagnosis of Chlamydia trachomatis-related infertility in
THE DEVELOPMENT OF AN EFFECTIVE VACCINE AGAINST CHLAMYDIA: UTILISATION OF A NON-TOXIC MUCOSAL ADJUVANT TO GENERATE A PROTECTIVE MUCOSAL RESPONSE
THE DEVELOPMENT OF AN EFFECTIVE VACCINE AGAINST CHLAMYDIA: UTILISATION OF A NON-TOXIC MUCOSAL ADJUVANT TO GENERATE A PROTECTIVE MUCOSAL RESPONSE Connor Patrick O Meara Bachelor of Science Biological Science
Endeavour College of Natural Health endeavour.edu.au
Endeavour College of Natural Health endeavour.edu.au BIOH122 Human Biological Science 2 Session 9 Immune System 2 Bioscience Department Endeavour College of Natural Health endeavour.edu.au o Adaptive (Specific)